Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AVI-4020 Injection
AVI-4020 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVI-4020 Injection | DRUG | - |
Inclusion Criteria: * Adult males 18 years to 64 years of age; * Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * Signed and dated written informed consent form; and * Willing to partici...
AVI-4020 is an investigational small molecule developed by Sarepta Therapeutics, Inc. (ticker SRPT) for West Nile Virus, an infectious disease. It has been studied in a Phase 1 clinical trial and is not an approved therapy. AVI-4020 is also known as AVI-4020 Injection.
AVI-4020 is being developed for West Nile Virus infection. Its only recorded clinical study enrolled healthy adult male volunteers rather than patients with the disease, and it was designed to measure drug levels in cerebrospinal fluid. AVI-4020 has not been approved for any use.
AVI-4020 is developed by Sarepta Therapeutics, Inc., which trades under the ticker SRPT. Sarepta is the sponsor associated with the drug's clinical program in West Nile Virus.
AVI-4020 is in Phase 1 development. Its single recorded trial, NCT00387283, is completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA for West Nile Virus or any other indication.
AVI-4020 has been studied in one clinical trial, NCT00387283, titled "Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020." The Phase 1 study was completed in the United States and enrolled 14 healthy male volunteers aged 18 years and older. It was an uncontrolled study.
Yes. AVI-4020 Injection is an alternative name for AVI-4020, the investigational small molecule developed by Sarepta Therapeutics, Inc. (SRPT) for West Nile Virus. Both names refer to the same Phase 1 asset.